GlassScriptPhysician profile
Aakash Goyal
NPI 1588239255
$484.86
in general payments reported to CMS, 2019-2025
10 companies · $395 in 2025
The $395 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $35.01 · 2024: $54.74 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $484.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $223.61 | 2025 | Tyvaso |
| Stryker Corporation | $48.88 | 2025 | Flowtriever |
| La Jolla Pharmaceutical Company | $44.99 | 2025 | Giapreza |
| Grifols USA, LLC | $42.43 | 2025 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $35.55 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $25.55 | 2024 | Tavneos |
| Pfizer INC. | $18.90 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $16.11 | 2023 | Rexulti |
| Novo Nordisk INC | $15.26 | 2024 | Rybelsus |
| Merck Sharp & Dohme LLC | $13.58 | 2025 | Zerbaxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aakash Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.